Literature DB >> 11422200

Effects of recombinant granulocyte-colony stimulating factor administration during Mycobacterium avium infection in mice.

A S Gonçalves1, R Appelberg.   

Abstract

Granulocyte colony-stimulating factor (G-CSF) administration in vivo has been shown to improve the defence mechanisms against infection by different microbes. Here we evaluated a possible protective role of this molecule in a mouse model of mycobacterial infection. The administration of recombinant G-CSF promoted an extensive blood neutrophilia but failed to improve the course of Mycobacterium avium infection in C57Bl/6 or beige mice. G-CSF administration also failed to improve the efficacy of a triple chemotherapeutic regimen (clarithromycin + ethambutol + rifabutin). G-CSF treatment did not protect interleukin-10 gene disrupted mice infected with M. avium. Spleen cells from infected mice treated with G-CSF had a decreased priming for antigen-specific production of interferon gamma compared to control infected mice. Our data do not substantiate previous reports on the protective activity of G-CSF in antimycobacterial immunity using mouse models.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422200      PMCID: PMC1906052          DOI: 10.1046/j.1365-2249.2001.01552.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  48 in total

1.  Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines.

Authors:  C E Demeure; L P Yang; C Desjardins; P Raynauld; G Delespesse
Journal:  Eur J Immunol       Date:  1997-12       Impact factor: 5.532

2.  Natural history of disseminated Mycobacterium avium complex infection in AIDS.

Authors:  M A Jacobson; P C Hopewell; D M Yajko; W K Hadley; E Lazarus; P K Mohanty; G W Modin; D W Feigal; P S Cusick; M A Sande
Journal:  J Infect Dis       Date:  1991-11       Impact factor: 5.226

3.  Granulocyte colony-stimulating factor worsens the outcome of experimental Klebsiella pneumoniae pneumonia through direct interaction with the bacteria.

Authors:  T K Held; M E Mielke; M Chedid; M Unger; M Trautmann; D Huhn; A S Cross
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

4.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

5.  Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients.

Authors:  P Keiser; S Rademacher; J W Smith; D Skiest; V Vadde
Journal:  Am J Med       Date:  1998-01       Impact factor: 4.965

6.  G-CSF association with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection.

Authors:  P Keiser; S Rademacher; J Smith; D Skiest
Journal:  Int J STD AIDS       Date:  1998-07       Impact factor: 1.359

7.  Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996.

Authors:  J L Jones; D L Hanson; M S Dworkin; J E Kaplan; J W Ward
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

8.  Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice.

Authors:  L E Bermudez; M Petrofsky; P Stevens
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

9.  Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation.

Authors:  M Mielcarek; L Graf; G Johnson; B Torok-Storb
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113

10.  Giant granules of neutrophils in Chediak-Higashi syndrome are derived from azurophil granules but not from specific and gelatinase granules.

Authors:  L Kjeldsen; J Calafat; N Borregaard
Journal:  J Leukoc Biol       Date:  1998-07       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.